Taysha Gene Therapies, Inc. (TSHA) NASDAQ

5.69

-0.28(-4.69%)

Updated at June 02 04:00PM

Currency In USD

About Privacy Policy Contact us Terms & Conditions

Taysha Gene Therapies, Inc.

Address

3000 Pegasus Park Drive

Dallas, TX 75247

United States of America (the)

Phone

214 612 0000

Website

https://www.tayshagtx.com

Sector

Healthcare

Industry

Biotechnology

Employees

First IPO Date

September 24, 2020

Key Executives

Name	Title	Pay	Year Born
Sean Nolan	Chief Executive Officer & Chairman	1.19M	1968
Kamran Alam	Chief Financial Officer & Corporate Secretary	741,904	1978
Sukumar Nagendran	President, Head of Research & Development and Director	1.04M	1967
Steven Gray	Chief Scientific Advisor of UT Southwestern Gene Therapy Program	0	N/A
Hayleigh Collins	Director of Corporate Communications & Investor Relations	0	N/A
David McNinch	Chief Commercial Officer	0	1969
Frederick Porter	Chief of Staff & Technical Operations Officer	0	N/A
Sean McAuliffe	Chief Business Officer	0	N/A
Berge Minassian	Chief Medical Advisor of UT Southwestern Gene Therapy Program	0	N/A
Emily McGinnis	Chief Patient & External Affairs Officer	0	N/A
Rumana Haque-Ahmed	Chief Regulatory Officer	0	N/A
Tracy Porter	Chief People Officer	0	N/A

Description

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.